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Postthrombotic Syndrome in Patients
Treated With Rivaroxaban or Warfarin
for Venous Thromboembolism
Craig I. Coleman, PharmD1 , Jan Beyer-Westendorf, MD2,3,
Thomas J. Bunz, PharmD, PhD4, Charles E. Mahan, PharmD, PhC5,
and Alex C. Spyropoulos, MD6
Abstract
Postthrombotic syndrome (PTS) is a frequent complication of venous thromboembolism (VTE). Using MarketScan claims data
from January 2012 to June 2015, we identified adults with a primary diagnosis code for VTE during a hospitalization/emergency
department visit, 6 months of insurance coverage prior to the index event and newly started on rivaroxaban or warfarin within
30 days of the index VTE. Patients with <4-month follow-up postindex event or a claim for any anticoagulant during 6-month
baseline period were excluded. Differences in baseline characteristics between rivaroxaban and warfarin users were adjusted for
using inverse probability of treatment weights based on propensity scores. Patients were followed for the development of PTS
starting 3 months after the index VTE. Cox regression was performed and reported as hazard ratios with 95% confidence
intervals (CIs). In total, 10 463 rivaroxaban and 26 494 warfarin users were followed for a mean of 16+ 9 (range, 4-39) months.
Duration of anticoagulation was similar between cohorts (median ¼ 6 months). Rivaroxaban was associated with a 23% (95% CI:
16-30) reduced hazard of PTS versus warfarin. Rivaroxaban was associated with a significant risk reduction in symptoms of PTS
compared to warfarin in patients with VTE treated in routine practice.
Keywords
postthrombotic syndrome, rivaroxaban, warfarin, anticoagulants, venous thromboembolism
Introduction
Postthrombotic syndrome (PTS) is a frequent complication of
deep vein thrombosis (DVT) with or without pulmonary embo-
lism (PE), with prospective studies reporting anywhere from
20% to 50% of patients with DVT developing PTS.1 Signs and
symptoms of PTS can vary from patient to patient but often
include pain, swelling, heaviness, fatigue, itching, and cramp-
ing at night in the affected limb.1 Postthrombotic syndrome can
reduce patients’ health-related quality of life and increase
health-care costs.2-3 The mean cost of PTS treatment in the
United States (US) has been estimated at *US$7000 per
patient per year.3
Elastic compression stockings have had a controversial role
in the prevention of PTS because of sparse and often conflict-
ing data backing their use1 and therefore increasing the impor-
tance of optimizing anticoagulation in this setting. Patients
with venous thromboembolism (VTE) treated with a vitamin
K antagonist (VKA) often spend substantial portions of time
below their target international normalized ratio (INR) range of
2 to 3.4-5 Suboptimal anticoagulation of DVT may result in
VTE recurrence, insufficient or slower thrombus resolution,
persistent venous obstruction and insufficiency, venous valve
damage and impaired microcirculation, and eventually PTS.1,6-7
In the EINSTEIN clinical trial program, rivaroxaban has been
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shown to be at least as effective as enoxaparin/VKA in the acute
treatment and secondary prevention of recurrent VTE in patients
with a creatinine clearance >30 mL/min, with a 46% (P ¼ .002)
decreased risk of major bleeding.8-10 Rivaroxaban is character-
ized by a rapid onset of anticoagulation activity (peak factor Xa
inhibition within 2 to 4 hours after oral administration)11 and
predictable pharmacologic profile compared to VKAs. More-
over, a post hoc analysis of a small sample from the EINSTEIN
DVT trial suggested that rivaroxaban could be associated with a
reduced incidence of PTS.12
A scientific statement on evidence-based prevention, diag-
nosis, and treatment strategies for PTS published by the Amer-
ican Heart Association (AHA)1 notes that there is “a pressing
need” for research evaluating the effectiveness of direct-acting
oral anticoagulants (DOACs) to reduce the occurrence of PTS.
Therefore, the objective of this study was to assess the relative
hazard of PTS among patients with VTE treated with rivarox-
aban or warfarin in routine US clinical practice.
Materials and Methods
This study report was written in compliance with the STrength-
ening the Reporting of OBservational studies in Epidemiology
statement.13
We performed a retrospective claims database study using
US Truven MarketScan data from January 2012 to June 2015.
MarketScan combines 2 separate databases, a commercial and
a Medicare supplemental database, to cover all age groups, and
as of March 2017 contains claims from 260 contributing
employers, 40 contributing health plans, and government and
public organizations representing nearly 240 million covered
American lives.14 Truven MarketScan captures health plan
enrollment records, participant demographics, International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) diagnosis codes, Current Procedural Technol-
ogy, Fourth Revision (CPT-4) procedure codes, admission and
discharge dates, inpatient mortality data, outpatient medical
services data, and prescription dispensing records. All data
included in the Truven MarketScan databases are de-
identified and are in compliance with the Health Insurance
Portability and Accountability Act of 1996 to preserve partici-
pant anonymity and confidentiality. For this reason, this study
was exempt from institutional review board oversight.
To be included in the present study, patients had to be
18 years of age with a primary discharge diagnosis code for
DVT (ICD-9-CM ¼ 451.1, 451.2, 453.40, 2453.41, 453.42,
453.8, 453.9) or PE (ICD-9-CM ¼ 415.1x) during a hospitali-
zation or emergency department visit (index event),15 filling
their first prescription for rivaroxaban or warfarin within
30 days of the index event and have 6 months of continuous
medical and prescription benefits prior to the index event
(baseline period). The patients with PE (regardless of whether
there was a concomitant diagnosis code for DVT) were
included since it has been demonstrated that patients with a
majority symptomatic PE also have DVT (symptomatic or
asymptomatic).16-17 Patients with <4-month follow-up
postindex event, only an outpatient diagnosis code for VTE
(which has been shown poorly predictive of acute VTE15) or
a VTE claim or prescription claim for an outpatient anticoagu-
lant during the baseline period, were excluded. This limited our
population to patients who had not experienced a recent VTE
event and those receiving anticoagulation for other indications
(eg, atrial fibrillation). Given the large number of patients
available in claims database analyses, no calculations to esti-
mate required sample size were performed; rather all eligible
patients meeting inclusion/exclusion criteria were analyzed.
The primary end point for this study was the development of
PTS (symptoms of PTS). A secondary end point was the devel-
opment of PTS with venous ulcer. No specific ICD-9-CM
code(s) exist to indicate a diagnosis of PTS are available1; there-
fore, the occurrence of symptoms of PTS during follow-up was
determined using an algorithm developed by MacDougall and
colleagues18 and used in multiple prior claims database stud-
ies.19-20 The algorithm takes into account the syndrome, often
waxing-and-waning nature of the disease.1,18 The MacDougall
algorithm18 defines PTS as a code for 1 extremity venous
study including Doppler waveform analysis or venous plethys-
mography (CPT-4 ¼ 93 965-93 971) along with diagnosis
code(s) for both pain (ICD-9-CM ¼ 729.5) and swelling of the
limb (ICD-9-CM ¼ 729.81) within 7 days of each other, lower
extremity varicose veins (ICD-9-CM ¼ 454.xx) with or without
ulcer and/or inflammation, postphlebitic syndrome (ICD-9-CM
¼ 459.1x) with or without ulcer and/or inflammation, or other
disorder of the circulatory system (ICD-9-CM¼ 459.8x) at least
3 months after the index VTE event (Supplemental Table 1).
Diagnosis and procedure codes could be identified in any (pri-
mary or nonprimary) coding position. The 3-month delay in our
study for identifying PTS was chosen based on scientific state-
ments from the International Society on Thrombosis and Hemos-
tasis21 and the AHA1 that recommend PTS not be diagnosed
before 3-month postevent to avoid inappropriately attributing
acute signs and symptoms to the PTS. Moreover, prior claims-
based studies using the MacDougall algorithm have employed a
similar 3-month gap.19-20 In our study, patients were followed
until the development of PTS, disenrollment from their insur-
ance plan, or end-of-study follow-up.
To adjust for potential confounding resulting from imbal-
ances in baseline patient characteristics, we utilized inverse
probability of treatment weighting (IPTW) based on the pro-
pensity score.22 Inverse probability of treatment weighting uses
propensity scores (predicted probability of initiating a specific
oral anticoagulants given baseline characteristics) to generate
patient-specific weights to adjust for any baseline imbalances.
Propensity scores were calculated using multivariable logistic
regression incorporating patient demographics, comorbidities,
known VTE risk factors, and concomitant nonoral anticoagu-
lant medications identified during the 6-month baseline
period. Residual differences in baseline characteristics
between weighted cohorts were assessed by calculating
absolute standardized differences (the systematic differences
in observed baseline characteristics), with differences
<0.1 considered well balanced.22
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Table 1. Baseline Characteristics of Weighted Rivaroxaban and Warfarin Cohorts.
Variable
Rivaroxaban,
N ¼ 10 463
Warfarin,
N ¼ 26 494
Absolute standardized
differencea
Demographics
Age 60years (%) 44.8 34.5 0.03
Female gender (%) 49.0 49.1 0.002
Year of inclusion (%)
2012 23.1 22.1 0.02
2013 37.7 38.1 0.01
2014 35.0 35.5 0.01
2015 4.2 4.3 0.005
Insurance plan type (%)
HMO 10.5 11.6 0.03
POS 5.7 5.5 0.01
PPO 54.8 54.5 0.01
Other 28.6 27.9 0.02
Hospitalizations in prior 6 months, mean (SD) 0.29 (1.04) 0.25 (0.56) 0.05
Diagnosis of PE (%) 44.3 44.1 0.003
Time from index event to first anticoagulant claim (days), mean (SD) 4.2 (7.5) 4.6 (4.2) 0.06
Time to index anticoagulant discontinuation (days), mean (SD) 212.7 (231.5) 211.8 (147.4) 0.005
Comorbidities and risk factors
Elixhauser comorbidities (%)
0 15.9 17.8 0.05
1 19.1 19.8 0.02
2 17.8 18.6 0.02
3 15.9 14.7 0.03
4 10.6 10.8 0.005
5 20.6 18.3 0.06
Metastatic cancer (%) 3.6 3.5 0.003
Lymphoma or leukemia (%) 1.2 1.3 0.01
Solid tumor (%) 9.3 8.8 0.02
Coagulopathy (%) 7.5 6.0 0.06
Obesity (%) 19.7 19.0 0.02
Paralysisb(%) 1.4 1.4 0.01
History or current smoker (%) 12.3 12.9 0.02
Varicose veins (%) 2.9 3.0 0.01
Major surgery including orthopedic 8.9 8.4 0.02
Chronic lung disease (%) 17.5 16.4 0.04
Pneumonia (%) 10.5 10.1 0.01
Central venous catheter (%) 2.1 2.0 0.002
Hypertension (%) 50.0 50.0 0.001
Type 1 or 2 diabetes mellitus (%) 18.3 18.0 0.01
Hyperlipidemia (%) 34.6 34.3 0.01
Rheumatoid arthritis/collagen vascular disease (%) 4.1 4.1 0.004
Heart failure (%) 7.4 6.8 0.02
Depression (%) 10.0 9.6 0.01
Psychosis (%) 4.1 3.6 0.03
Chronic kidney disease (%)
Stage 3 4.7 5.3 0.03
Stage 4 1.3 1.2 0.01
Stage 5 0.4 0.3 0.01
Renal dialysis 0.2 0.3 0.004
Liver dysfunction (%) 3.7 3.0 0.04
Hypothyroidism (%) 10.7 10.9 0.01
Anemia (%) 15.9 14.5 0.04
Alcohol use or dependence (%) 1.6 1.7 0.01
Drug use or dependence (%) 1.4 1.3 0.01
Stroke (%) 1.9 2.1 0.02
Transient ischemic attack (%) 1.1 1.2 0.01
Acute coronary syndrome (%) 4.3 3.8 0.02
(continued)
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Baseline patient characteristics were analyzed using
descriptive statistics. Cox proportional hazard regression was
performed and results reported as adjusted hazard ratios (HRs)
with accompanying 95% confidence intervals (CIs). Adjusted
incidence rate differences (AIRD) were estimated using IPTW
event counts and follow-up time for each index oral anticoa-
gulant group. Because all baseline characteristics were
balanced after adjustment using IPTW, our Cox regression
models included only index oral anticoagulant treatment
received (rivaroxaban or warfarin) as an independent variable.
We performed subgroup analyses to examine the impact of
age (<60 or 60þ years), initial VTE diagnosis (presence or
absence of PE), and sex on the effectiveness of rivaroxaban
(vs warfarin) in preventing PTS. We also performed sensitivity
analyses in which we restricted the PTS end point to only those
codes associated with ulcer (ICD-9-CM ¼ 459.11, 459.13,
454.0, 454.2) which by the Villalta Scale would automatically
be severe PTS,1 allowing patients to be newly started on rivar-
oxaban or warfarin within 60 days of the index event instead of
30 days, and upon requiring a 6-month time gap following the
index VTE before PTS could be diagnosed.1,21
All statistical analyses were performed using SAS version
9.4 (SAS Inc., Cary, North Carolina). A P value <.05 was
considered statistically significant in all cases.
Results
In total, this study evaluated 10 463 rivaroxaban and 26 494
warfarin users meeting inclusion/exclusion criteria (Figure 1).
Included patients were followed for a mean of 16 + 9 months
(range, 4-39 months), and rivaroxaban and warfarin users had
similar durations of anticoagulation (mean¼ 7 months; median
¼ 6 months for both cohorts) and times to first prescription
Table 1. (continued)
Variable
Rivaroxaban,
N ¼ 10 463
Warfarin,
N ¼ 26 494
Absolute standardized
differencea
Inflammatory bowel disease (%) 1.8 1.7 0.01
Recurrent VTE 3 months postindex event (%) 3.3 3.5 0.01
Medication use
Thrombolytics (%) 2.7 1.9 0.04
Estrogens (%) 4.0 4.4 0.02
Erythropoietin-stimulating agents (%) 0.2 0.2 0.01
Antiplatelets (%) 3.9 4.4 0.02
NSAIDs (%) 22.5 21.6 0.02
ACE inhibitors or ARBs (%) 31.6 30.8 0.02
b-blockers (%) 22.9 21.4 0.04
Calcium channel blockers (%) 15.6 14.3 0.04
Diuretics (%) 19.1 18.6 0.01
Digoxin (%) 0.6 0.7 0.01
Statin (%) 25.9 25.5 0.01
Insulin (%) 3.9 4.2 0.01
Noninsulin diabetes drugs (%) 12.0 11.0 0.03
Antidepressants (%) 23.2 22.7 0.01
Antiulcer drugs (%) 20.5 19.6 0.02
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HMO, health maintenance organization; N, number; NSAIDs, nonster-
oidal anti-inflammatory drugs; PE, pulmonary embolism; POS, point of service; PPO, preferred provider organization; VTE, venous thromboembolism.
aResidual differences in baseline characteristics between weighted cohorts were assessed by calculating absolute standardized differences (the systematic
differences in observed baseline characteristics), with differences <0.1 considered well balanced.22
bIncludes mono-, hemiplegia, or other paralytic syndromes due to intracranial bleeding, cerebral infarction, or cerebrovascular disease or functional quadriplegia.
Adult patients with a primary ICD-9-CM diagnostic code for deep vein
thrombosis or pulmonary embolism during a hospitalization or emergency
department visit
n=145,592
Patients with ≥6-months of continuous medical and prescription benefits prior
to and ≥4-months follow-upafter the index venous thromboembolic event
n=59,937
Patients with a new prescription claim (new initiators) for rivaroxaban or
warfarin within 30-days of the index event
n=36,957
(10,463 rivaroxaban and 26,494 warfarin)
Figure 1. Patient inclusion and exclusion ICD. ICD-9-CM indicates
International Classification of Diseases, Ninth Revision, Clinical Modification.
578 Clinical and Applied Thrombosis/Hemostasis 24(4)
claim (mean ¼ 4 + 8, range, 0-30 days vs 5 + 4, range,
0-30 days, respectively). Based on the assessment of absolute
standardized differences between the rivaroxaban and warfarin
users, patients were deemed well balanced on all independent
variables entered into the propensity score logistic regression
model (Table 1).
In total, 2418 PTS events were identified during follow-up,
of which 720 (29.8%) were associated with a venous ulcer
ICD9-CM code. Upon Cox proportion hazard regression, rivar-
oxaban was found to be associated with a significant 23%
reduced hazard of developing PTS compared to warfarin
(adjusted rates ¼ 3.69 vs 4.73 events per 100 person-years,
respectively; Figure 2). This corresponded to an AIRD of
1.04 fewer events per 100 person-years of follow-up in favor
of rivaroxaban. Reductions in the hazard of developing PTS
with rivaroxaban were consistent across subgroups (HR range,
0.60-0.85, P < .05 for all; Figure 3). Rivaroxaban continued to be
associated with a reduced risk of PTS when the end point was
restricted to only PTS with venous ulcer (adjusted rates ¼ 1.11
vs 1.38 events per 100 person-years, respectively; HR ¼ 0.81,
95% CI: 0.70-0.94, P ¼ .006; Figure 4), when time to new oral
anticoagulation start could be extended up to 60 days from the
index VTE event (HR ¼ 0.86, 95% CI: 0.79-0.93, P ¼ .0002)
and when a 6-month postindex event gap was required before
PTS diagnosis (HR ¼ 0.76, 95% CI: 0.69-0.85, P < .0001).
Discussion
This study performed in the US MarketScan administrative
claims databases evaluated the risk of PTS in patients with
VTE when anticoagulated with either rivaroxaban or warfarin.
Analysis demonstrated that rivaroxaban use was associated
with a significantly reduced hazard of developing PTS com-
pared to warfarin users (HR ¼ 0.77, AIRD ¼ 1.04 events per
100 person-years) and PTS associated with venous ulcer (HR¼
0.81, AIRD ¼ 0.27 events per 100 person-years). This finding
of a significantly reduced PTS rate with rivaroxaban was
observed across various patient subgroups (HR range, 0.60-
0.85, P < .05 for all) and sensitivity analyses (HR range,
0.76-0.86, P < .05 for all). As the subgroup and sensitivity
analyses’ HRs were often based on differing size populations
or event rates (affecting estimate precision), we caution against
the overinterpretation of these results.
There is limited published data evaluating the impact of
DOACs on the incidence of PTS following a DVT and/or
PE. Cheung and colleagues12 performed a post hoc analysis
of a small subset of patients with DVT (without symptomatic
PE) enrolled in the EINSTEIN-DVT randomized controlled
trial (RCT) to assess the impact of rivaroxaban versus enoxa-
parin bridging to a VKA in preventing PTS. The investigators
followed a total of 336 patients for a median of 57 months
(*4.75 years) for the occurrence of PTS diagnosed based upon
a Villalta score 5.12,23 Forty-five of 162 rivaroxaban (esti-
mated rate *5.8%/year) and 66 of 174 enoxaparin/VKA par-
ticipants (estimated rate *8.0%/year) developed PTS (HR ¼
0.76, 95% CI: 0.51-1.13, P¼ .18) during follow-up. Therefore,
the HRs (0.77 and 0.76) and absolute rates (3.4 vs 4.7 per 100
person-years in our analysis compared to 5.8 vs 8.0 per 100
person-years in EINSTEIN) for PTS with rivaroxaban versus
conventional anticoagulation observed in both studies were
relatively similar. Importantly, we feel that the similarity in
rates detected in both studies supports the validity of our
claims-based (MacDougall algorithm) approach to PTS identi-
fication. The lower rates of PTS observed in our claims analysis
compared to EINSTEIN might be explained by a failure of
clinicians to code for more mild cases of PTS (which were
frequent in EINSTEIN) and/or EINSTEIN’s use of an objective
assessment for PTS.12 It has been suggested that providing
anticoagulation at an appropriate intensity (and duration), par-
ticularly during the first week after a DVT, is an important
means of preventing PTS.1,6-7As part of the prospective Recur-
rent Venous thromboembolism Risk Stratification Evaluation
study,6 the odds of a patient with DVT + PE developing PTS
were shown to be 1.84-fold (P < .05) higher during the first 3
months of treatment in patients with an INR <2.0 at least 20%
of the time. Unfortunately, studies have frequently demon-
strated that patients with VTE spend only about one-half of
their time in the target INR range of 2.0 to 3.0, with a strong
tendency toward subtherapeutic anticoagulation (*42% below
range in the first month of treatment, 35% in 1-3 months, and
24.1% in 1-6 months).5 Moreover, there are significantly more
drug–drug interactions with warfarin that can both impact INR
control and decrease its effectiveness and increase bleeding
risk. Direct-acting oral anticoagulants such as rivaroxaban
have a rapid onset of anticoagulation activity and a predictable
pharmacologic profile which allows them to surmount the
early subtherapeutic anticoagulation frequently observed
with VKAs and allow for substantially simplified perioperative
Figure 2. Kaplan-Meier curve depicting cumulative incidence of
postthrombotic syndrome in patients treated with rivaroxaban or
warfarin for venous thromboembolism. CI indicates confidence
interval; HR, hazard ratio.
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anticoagulation management by allowing prescribers to stop
and restart at the appropriate time with no need for parenteral
overlap or bridging therapy in the procedural setting.24
Both residual thrombosis burden and incomplete resolution
of leg symptoms and signs at 1 month after DVT have been
shown to be important risk factors for PTS development.1
Consequently, data from the phase II Oral Direct Factor Xa
Inhibitor BAY 59-7939 in Patients With Acute Symptomatic
Deep-Vein Thrombosis -DVT trial of rivaroxaban showing
faster and more extensive clot resolution earlier after treatment
provides an additional potential mechanism underlying our
finding that rivaroxaban was associated with less PTS than
conventional anticoagulation.25 In this study, Agnelli and col-
leagues performed ultrasound estimation of clot burden on the
day of DVT diagnosis as well as days 21 and 84. At day 21
following a DVT, more than half of patients who received
rivaroxaban twice daily experienced an improvement of 4
points in thrombus score (experienced improved clot resolu-
tion) compared to 45.9% in those receiving enoxaparin/VKA;
however, by day 84, these differences were no longer evident.
It is important to note that PTS has been associated with
poorer quality of life in patients with VTE. In a meta-analysis
performed by Lubberts and colleagues,26 the development of
PTS was associated with worse patient-reported physical health
(P < .001, n ¼ 7 studies), mental health (P < .001, n ¼ 7
studies), and disease-specific quality of life (P < .001, n ¼
10 studies). Thus, potentially reducing PTS by utilizing antic-
oagulants shown to reduce PTS risk could yield dramatic
patient-perceived benefits.26-27 Unfortunately, we were unable
to assess differences in patient quality of life between cohorts
as such data were not available in the Truven MarketScan
database. The ability of DOACs, including rivaroxaban, to
improve quality of life of patient with VTE by preventing PTS
merits prospective study evaluation.
As a retrospective analysis of US claims data, our study has
limitations worthy of discussion. First, as we used US claims
Figure 3. Development of postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism*.
* denotes P < .05 for all rivaroxaban versus warfarin subgroup comparisons. CI indicates confidence interval; DVT, deep vein thrombosis; HR,
hazard ratio; N, number; PE, pulmonary embolism.
Figure 4. Kaplan-Meier curve depicting cumulative incidence of
postthrombotic syndrome with venous ulcer in patients treated with
rivaroxaban or warfarin for venous thromboembolism. CI indicates
confidence interval; HR, hazard ratio.
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data only, our results will likely be most applicable to a US
population. Second, misclassification and sampling biases are
always important limitations in administrative claims database
studies.28 Third, while propensity score22 can aid in generating
cohorts that are comparable in key characteristics, only those
variables measured in the Truven MarketScan databases14
could be adjusted upon using IPTW in this analysis. Therefore,
residual confounding cannot be excluded regardless of the
sophistication of the methodology and the number of variables
used in developing patients’ propensity scores.28 Fourth, the
majority of administrative claims databases, including Truven
MarketScan, are hindered by insufficient reporting of some
clinical (eg, inpatient anticoagulation, DVT location or throm-
bus burden, use of elastic compression stockings) and labora-
tory (eg, INR, D-dimer) data.14,28 This study deliberately
included all patients with VTE, therefore reflecting the overall
burden of PTS. It was not intended (nor designed) to evaluate
the differences in PTS incidence for different types of VTE as
ICD-9 coding has not been proven to be accurate at classifying
clot location/clot burden. International normalized ratio mea-
surements were not available, and consequently, times in the
therapeutic range (TTRs) could not be calculated. Poor INR
control in real-world US practice is common, with TTR often
estimated at values of *55%.4,29 Therefore, while we could
not approximate the TTR for our warfarin cohort, prior litera-
ture suggests that it was likely as much as 10% worse than seen
in RCTs such as EINSTEIN.8-9 Fifth, our definition of PTS
used for this study is claims based and may be better described
as detecting symptoms of PTS as compared to clinical
diagnosis.18 Due to the type of data provided in claims data-
bases, it is not possible to implement the Villalta Scale to
identify PTS.23 The use of a claims-based definition of PTS
symptoms compared to a clinical definition may explain the
somewhat lower rates of PTS detected in our study compared to
the post hoc analysis of EINSTEIN-DVT.12 It is important to
note that even when using a recommended scale such as the
Villalta score, diagnosis of PTS remains subjective as it is
dependent on symptoms reporting by patients or observations
by clinicians.1,23 Next, by excluding patients with only an out-
patient diagnosis for VTE, we may have missed some cases,
but by doing so, we substantially increased the likelihood that
included cases in this study were in fact new, acute VTE
events.15 Finally, our study’s shorter duration of follow-up
compared to the post hoc analysis of EINSTEIN-DVT12 is a
limitation; however, with a mean of 16 months (range, 4-39
months) of follow-up, our study had the majority of the highly
vulnerable period for PTS (6 to 24 months) covered.1 Further-
more, the shorter follow-up was similar between treatment
groups, making it a limitation that holds true for both
comparators. A strength of our study was its large sample size
(particularly when compared to the PTS subanalysis of
EINSTEIN-DVT) which provided us with excellent power to
detect potential differences in PTS (and PTS with venous ulcer)
rates between anticoagulants.
In conclusion, this large administrative claims database
study suggests that rivaroxaban is associated with less PTS and
less PTS associated with venous ulcers compared to warfarin in
patients with VTE managed in routine US clinical practice.
These findings are consistent with those from a post hoc anal-
ysis of the EINSTEIN-DVT trial. Larger randomized con-
trolled trials evaluating the potential benefits of rivaroxaban
on PTS incidence are warranted.
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